Evotec

Evotec is a pharmaceutical company that researches and develops drug discovery solutions for the biotechnology sector. Read more

616 Followers on Owler
616 Followers on Owler
616 Followers on Owler
616 Followers on Owler

Evotec

Evotec is a pharmaceutical company that researches and develops drug discovery solutions for the biotechnology sector. Read more

Werner Lanthaler's photo - CEO of Evotec

CEO

Werner Lanthaler

CEO Approval Rating

81/100

Founded:

1993

Status:

PublicIndependent CompanyFRAEVT

EVOTEC TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Sygnature Discovery is perceived as one of Evotec's biggest rivals. Sygnature Discovery was founded in 2004, and is headquartered in Nottingham, England. Sygnature Discovery is in the Pharmaceuticals industry. Sygnature Discovery generates $990.2M less revenue vs. Evotec.

Astellas Pharma, Inc. is a top competitor of Evotec. Astellas Pharma, Inc. is a Public company that was founded in 2005 in Tokyo, Tōkyō Prefecture. Astellas Pharma, Inc. operates in the Pharmaceuticals industry. Compared to Evotec, Astellas Pharma, Inc. has 12,311 more employees.

Selvita is Evotec's #3 rival. Selvita is headquartered in Krakow, Other, and was founded in 2007. Selvita competes in the Biotechnology industry. Selvita generates 0.49% the revenue of Evotec.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Renova Therapeutics a competitor of Evotec?

Evotec Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$1B

Evotec's revenue is the ranked 3rd among it's top 10 competitors. The top 10 competitors average 1.1B. Over the last three quarters, Evotec's revenue has grown by 64.3%. Specifically, in Q4 2020's revenue was $206.2M; in Q3 2020, it was $151.5M; in Q2 2020, it was $125.5M.

Evotec Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Just. Evotec Biologics

May 2019

Source »
$90M
Just is a biotechnology firm that develops monoclonal antibody products for the biotherapeutic sector.
Aptuit LLC

Aug 2017

Source »
$300M
Aptuit provides drug discovery and pre-clinical testing services for pharmaceutical and biotechnology companies.

-

Operational Business, Aptuit

Jul 2017

Source »
$300M
-
Cyprotex PLC

Oct 2016

Source »
$67.5M
Cyprotex is a contract research organization specializing in pre-clinical ADME-Tox and DMPK for pharmaceutical, chemical and agrochemical markets
Euprotec Ltd.

May 2014

Source »
$5.3M
-

These are all the companies that Evotec has acquired. Evotec has acquired 7 companies and its latest acquisition was Just. Evotec Biologics in May 2019. Just is a biotechnology firm that develops monoclonal antibody products for the biotherapeutic sector.

Evotec Funding History

Since Evotec was founded in 1993, it has participated in 4 rounds of funding. In total Evotec has raised $220.6M. Evotec's last funding round was on Jun 2019 for a total of $23.8M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Grant
Jun 2019
$23.8M

Gates Foundation

Debt
Sep 2017
$89.8M
Equity
Sep 2013
$40M
-
IPO
Nov 1999
$67M

Since Evotec was founded in 1993, it has participated in 4 rounds of funding. In total Evotec has raised $220.6M. Evotec's last funding round was on Jun 2019 for a total of $23.8M

Evotec Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Exscientia is an England-based AI platform that provides drug discovery and development solutions for biotechnology and pharmaceutical companies.
$40M
Mar 02, 2021
Series C
-
Blacksmith Medicines is a California-based biotechnology company that develops and commercializes medicines for the treatment of cancer and inflammatory diseases.
-
Jan 07, 2021
Seed
-
Eternygen is a contract research organization that offers clinical trial and consulting services to the pharmaceutical and biotechnology industries.
$5.9M
Oct 25, 2020
Series A
-
Topas is a biotechnology company that develops and commercializes novel therapeutics for the treatment of immune-mediated and autoimmune diseases.
$26M
Oct 18, 2020
Series B
-
Exscientia is an England-based AI platform that provides drug discovery and development solutions for biotechnology and pharmaceutical companies.
$60M
May 25, 2020
Series C
-

These are all the companies that Evotec has invested in. Evotec has invested 7 companies and its latest investment was Just. Evotec Biologics in May 2019. Just is a biotechnology firm that develops monoclonal antibody products for the biotherapeutic sector.

Evotec News

May 11, 2021FinanzNachrichten

Evotec Q1 Adj. EBITDA Down

HAMBURG (dpa-AFX) - Evotec SE (EVTCY.PK, EVOTF.PK), a German drug discovery alliance and development ... See more »
May 11, 2021MarketScreener

RBC takes a positive view

(marketscreener.com) RBC's analyst Charles Weston upgrades his rating from Neutral to Buy. The target... See more »
May 7, 2021Global University Venturing

News, Data, and Events - Global University Venturing

Evotec has partnered BMS to launch another Bridge programme, focused on the universities of Birmingha... See more »
May 5, 2021Pharmabiz

Evotec & GCKD ink partnership to build unique molecular patient database

Evotec and the University Hospital Erlangen announced a partnership regarding molecular analyses of b... See more »
April 27, 2021Pharmabiz

Bristol Myers Squibb, Evotec exercise option to extend targeted protein degradation partnership

Evotec announced that Bristol Myers Squibb has decided to exercise their option to extend its partner... See more »
April 27, 2021FinanzNachrichten

Awakn Life Sciences Initiates New Chemical Entity Development Program with Evotec as Research Partner and Addiction Expert, Prof. David Nutt, as Program Lead

DEFINING CLEAR DEVELOPMENT PATHWAY FOR NEXT GENERATION OF PSYCHEDELIC MEDICINES TO TREAT ADDICTION To... See more »
April 26, 2021Proactive Investors

Kazia Therapeutics' EVT801 deal secures price target of A$2.60 from Corporate Connect and BUY rating from HC Wainwright

The company gained exclusive global rights to the drug for €1 million (A$1.6 million) upfront, €308 m... See more »

Evotec Press Releases

January 8, 2021PR Newswire

Blacksmith Medicines Launches With Seed Funding and a Research Collaboration With Lilly

SAN DIEGO, Jan. 8, 2021 /PRNewswire/ -- Blacksmith Medicines, Inc. (Blacksmith), a biotechnology comp... See more »
October 8, 2020Accesswire

Evotec Achieves Milestone in Its Neurodegeneration Collaboration with Bristol Myers Squibb

- ADDING ANOTHER DRUG DISCOVERY PROJECT TO THE PORTFOLIO TRIGGERS US$ 6 M PAYMENT TO EVOTEC HAMBURG, ... See more »
September 23, 2020Business Wire

Celmatix Achieves Second Milestone in Women's Health Drug Discovery Alliance with Evotec

NEW YORK--(BUSINESS WIRE)--Celmatix Inc., the leading women's health biotech focused uniquely on ovar... See more »
April 30, 2020StreetInsider

Just - Evotec Biologics to Collaborate with Ology Bioservices On Antibodies Against Coronavirus

PARTNERSHIP IS PART OF A CONTRACT AWARDED TO OLOGY BIOSERVICES BY THE DEPARTMENT OF DEFENSE TO DEVELO... See more »
November 14, 2019centralcharts

EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES

DGAP-News: Evotec SE / Key word(s): Conference EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES 14.11.2... See more »
May 23, 2019EIN Presswire

grit42 software supports the global fight against superbugs

As part of Evotec's AMR efforts, the bacteriology & omics team in Lyon has selected grit42's software... See more »
March 28, 2019PR-Inside

ACCELERATED GROWTH AND STRONG

(PR-inside.com) - EXCELLENCE IN SCIENCE, PARTNERED DRUG DISCOVERY & DEVELOPMENT, ACQUISITIONS, AND UN... See more »

Evotec Videos

Social Media

Evotec Headquarters

Essener Bogen 7 Manfred Eigen Campus

Hamburg, Hamburg22419

49-40-5-60-81-0

Driving Directions »

Trending Companies

Evotec Summary

ABOUT

Overview

Evotec is a pharmaceutical company that researches and develops drug discovery solutions for the biotechnology sector. Evotec was founded in 1993. Evotec's headquarters is located in Hamburg, Hamburg, DE 22419. It has raised 220.6M in 4 rounds. The la...

CEO

Evotec's CEO, Werner Lanthaler, currently has an approval rating of 81%. Evotec's primary competitors are Sygnature Discovery, Astellas Pharma, Inc. & Selvita.

Website

evotec.com

Frequently Asked Questions about Evotec

  1. When was Evotec founded?

    Evotec was founded in 1993
  2. Who is Evotec's CEO?

    Evotec's CEO is Werner Lanthaler
  3. How much revenue does Evotec generate?

    Evotec generates $1B in revenue
  4. How much funding does Evotec have?

    Evotec has historically raised $220.6M in funding
  5. Where is Evotec's headquarters?

    Evotec's headquarters is in Hamburg Hamburg, DE
  1. How many employees does Evotec have?

    Evotec has 3,572 employees
  2. What sector does Evotec operate in?

    Evotec is in Health Care Technology
  3. Who are Evotec's competitors?

    Evotec's top competitors are Sygnature Discovery, Astellas Pharma, Inc., Selvita
  4. Who has Evotec invested in?

    Evotec's has invested in companies such as Exscientia, Blacksmith Medicines, Eternygen